Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

Oncogene

Volumn 29, Issue 14, 2010, Pages 2013-2023

  Turner, N ^a   Lambros, M B ^a   Horlings, H M ^b,c   Pearson, A ^a   Sharpe, R ^a   Natrajan, R ^a   Geyer, F C ^a   Van Kouwenhove, M ^b   Kreike, B ^c   MacKay, A ^a   Ashworth, A ^a   Van De Vijver, M J ^b,c   Reis Filho, J S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Comparative genomic hybridization; FGFR2; Gene expression; Microarrays; Triple negative breast cancer

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; BUB3 PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; NOTCH3 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PKN1 PROTEIN; RAB20 PROTEIN; UNCLASSIFIED DRUG;

AMPLICON; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; COMPARATIVE GENOMIC HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; LIGANDS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION;

EID: 77950866696     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.489     Document Type: Article

References (47)

1. Adelaide J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F et al. (2007). Integrated profiling of basal and luminal breast cancers. Cancer Res 67: 11565-11575.
2. Agrawal G, Chen JH, Baick CH, Chen AE, Mehta RS, Nalcioglu O et al. (2007). Pathological complete response in triple negative poorly differentiated invasive ductal breast carcinoma detected during pregnancy. J Clin Oncol 25: 2618-2620.
3. Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C et al. (2009). Molecular characterization of breast cancer with highresolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 15: 441-451.
4. Benjamini Y, Hochberg Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc 57: 289-300.
5. Bernard-Pierrot I, Gruel N, Stransky N, Vincent-Salomon A, Reyal F, Raynal V et al. (2008). Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. Cancer Res 68: 7165-7175.
6. Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P et al. (2008). How basal are triple-negative breast cancers? Int J Cancer 123: 236-240.
7. Byron SA, Gartside MG,Wellens CL, Mallon MA, Keenan JB, Powell MA et al. (2008). Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res 68: 6902-6907.
8. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F et al. (2007). The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334.
9. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL et al. (2006). Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10: 529-541.
10. Chou TC, Talalay P. (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
11. Coe BP, Ylstra B, Carvalho B, Meijer GA, Macaulay C, Lam WL. (2007). Resolving the resolution of array CGH. Genomics 89: 647-653.
12. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. (2009). Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115: 423-428.
13. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al. (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434.
14. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG et al. (2007). Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447: 1087-1093.
15. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA et al. (2008). Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 4: e1000054.
16. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G et al. (2007). Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158.
17. Gunnarsson R, Staaf J, Jansson M, Ottesen AM, Goransson H, Liljedahl U et al. (2008). Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia-a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 47: 697-711.
18. Han W, Jung EM, Cho J, Lee JW, Hwang KT, Yang SJ et al. (2008). DNA copy number alterations and expression of relevant genes in triple-negative breast cancer. Genes Chromosomes Cancer 47: 490-499.
19. Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ. (2006). Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res 8: R61.
20. Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D et al. (2006). Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res 8: R66.
21. Hicks J, Krasnitz A, Lakshmi B, Navin NE, Riggs M, Leibu E et al. (2006). Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res 16: 1465-1479.
22. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF et al. (2006). The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7: 96.
23. Hughes TR, Roberts CJ, Dai H, Jones AR, Meyer MR, Slade D et al. (2000). Widespread aneuploidy revealed by DNA microarray expression profiling. Nat Genet 25: 333-337.
24. Jonsson G, Naylor TL, Vallon-Christersson J, Staaf J, Huang J, Ward MR et al. (2005). Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res 65: 7612-7621.
25. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H et al. (2007). Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9: R65.
26. Lambros MB, Simpson PT, Jones C, Natrajan R, Westbury C, Steele D et al. (2006). Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest 86: 398-408.
27. Mackay A, Tamber N, Fenwick K, Iravani M, Grigoriadis A, Dexter T et al. (2009). A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. Breast Cancer Res Treat 118: 481-498.
28. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C et al. (2008). Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863.
29. Marchio C, Natrajan R, Shiu KK, Lambros MB, Rodriguez-Pinilla SM, Tan DS et al. (2008). The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol 216: 399-407.
30. Mohammadi M, Froum S, Hamby JM, Schroeder MC, Panek RL, Lu GH et al. (1998). Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 17: 5896-5904.
31. Natrajan R, Lambros MB, Rodriguez-Pinilla SM, Moreno-Bueno G, Tan DS, Marchio C et al. (2009a). Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 15: 2711-2722.
32. Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DS et al. (2009b). An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat (e-pub ahead of print 18 August 2009).
33. Ng G, Huang J, Roberts I, Coleman N. (2006). Defining ploidyspecific thresholds in array comparative genomic hybridization to improve the sensitivity of detection of single copy alterations in cell lines. J Mol Diagn 8: 449-458.
34. Orsetti B, Nugoli M, Cervera N, Lasorsa L, Chuchana P, Ursule L et al. (2004). Genomic and expression profiling of chromosome 17 in breast cancer reveals complex patterns of alterations and novel candidate genes. Cancer Res 64: 6453-6460.
35. Reis-Filho JS, Drury S, Lambros MB, Marchio C, Johnson N, Natrajan R et al. (2008). ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40: 809-810; author reply 810-812.
36. Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A et al. (2006). FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 12: 6652-6662. (Pubitemid 44876833)
37. Reis-Filho JS, Tutt AN. (2008). Triple negative tumours: a critical review. Histopathology 52: 108-118.
38. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A et al. (2008). Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14: 8010-8018.
39. Tan DS, LambrosMB, Natrajan R, Reis-Filho JS. (2007). Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research. Lab Invest 87: 737-754.
40. Tannheimer SL, Rehemtulla A, Ethier SP. (2000). Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res 2: 311-320.
41. Tischkowitz MD, Foulkes WD. (2006). The basal phenotype of BRCA1-related breast cancer: past, present and future. Cell Cycle 5: 963-967.
42. Turner N, Tutt A, Ashworth A. (2004). Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4: 814-819.
43. Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R et al. (2008). A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 27: 1368-1377.
44. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF et al. (2008). Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 216: 141-150.
45. Yamaguchi N, Oyama T, Ito E, Satoh H, Azuma S, Hayashi M et al. (2008). NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells. Cancer Res 68: 1881-1888.
46. Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, Yoon DS et al. (2006). Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 12: 405-410.
47. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. (2005). The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 102: 18443-18448.